Top ophthalmology news of the week

Here are some of the latest top stories on Healio.com/OSN:

 

MicroPulse not just for end-stage glaucoma patients

Traditional diode transscleral cyclophotocoagulation has been deeply ingrained as a procedure intended for patients with severe end-stage glaucoma and poor vision. Read more.

 

FDA tentatively approves Alembics bimatoprost solution

The FDA has issued tentative approval for Alembic Pharmaceuticals’ abbreviated new drug application for bimatoprost ophthalmic solution 0.03%. Read more.

 

Early study results positive for AU-011 in patients with choroidal melanoma

A phase 1b/2 clinical trial of AU-011, a light-activated, vision-sparing, tumor cell selective therapy for patients with choroidal melanoma, showed the treatment was safe and resulted in no vision loss for up to 12 months. Read more.

 

Study: Clinical outcomes better for DMEK than ultrathin DSAEK

Compared with ultrathin Descemet’s stripping automated endothelial keratoplasty, Descemet’s membrane endothelial keratoplasty had faster recovery, superior visual acuity results and similar complication rates in patients with isolated endothelial dysfunction. Read more.

 

Continuous glucose monitor may help reduce incidence of diabetic eye disease

Studies have shown that a reduction in HbA1c has a concomitant reduction in diabetic retinopathy. Read more.

Here are some of the latest top stories on Healio.com/OSN:

 

MicroPulse not just for end-stage glaucoma patients

Traditional diode transscleral cyclophotocoagulation has been deeply ingrained as a procedure intended for patients with severe end-stage glaucoma and poor vision. Read more.

 

FDA tentatively approves Alembics bimatoprost solution

The FDA has issued tentative approval for Alembic Pharmaceuticals’ abbreviated new drug application for bimatoprost ophthalmic solution 0.03%. Read more.

 

Early study results positive for AU-011 in patients with choroidal melanoma

A phase 1b/2 clinical trial of AU-011, a light-activated, vision-sparing, tumor cell selective therapy for patients with choroidal melanoma, showed the treatment was safe and resulted in no vision loss for up to 12 months. Read more.

 

Study: Clinical outcomes better for DMEK than ultrathin DSAEK

Compared with ultrathin Descemet’s stripping automated endothelial keratoplasty, Descemet’s membrane endothelial keratoplasty had faster recovery, superior visual acuity results and similar complication rates in patients with isolated endothelial dysfunction. Read more.

 

Continuous glucose monitor may help reduce incidence of diabetic eye disease

Studies have shown that a reduction in HbA1c has a concomitant reduction in diabetic retinopathy. Read more.